SECsense Logo

Marker Therapeutics, Inc. 8-K Report: Key Insights on Recent Developments

$MRKR
Form 8-K
Filed on: 2024-12-23
Source
Marker Therapeutics, Inc. 8-K Report: Key Insights on Recent Developments

Based on the provided XML section of a financial report, here are the key pieces of information extracted:

  1. Entity Information:
  • Company Name: Marker Therapeutics, Inc.
  • CIK (Central Index Key): 0001094038
  • Incorporation State: Delaware (DE)
  • SEC File Number: 001-37939
  • EIN (Employer Identification Number): 45-4497941
  • Address: 2450 Holcombe Blvd, Suite BCM-A MS: BCM251, Houston, TX 77021
  • Phone Number: 713-400-6400
  1. Event Type:
  • Form Type: 8-K (Current Report)
  1. Date Information:
  • Filing Date: December 23, 2024
  • Report Period: This filing corresponds to a specific event on December 23, 2024.
  1. Stock Information:
  • Common Stock: The company has issued common stock with a par value of $0.001 per share.
  • Ticker Symbol: MRKR
  • Exchange: NASDAQ
  1. Currency:
  • All financial figures are reported in U.S. Dollars (USD).
  1. Units of Measurement:
  • The report mentions shares as a unit of measure, indicating that financial metrics may be reported in terms of shares and USD.

Insights:

  • The filing is a current report (8-K), which typically discloses significant events that shareholders should know about, such as acquisitions, changes in management, or financial updates.
  • Marker Therapeutics, Inc. is publicly traded on NASDAQ under the ticker MRKR, suggesting it operates in the public equity market and must comply with SEC regulations for transparency.
  • The specifics of the event reported in the 8-K are not included in the XML but would be crucial for understanding the implications of this filing for investors and stakeholders. Further analysis of the actual content of the 8-K would provide deeper insights into the company's current status and future outlook.